Indicators of lipid peroxidation and the activity of antioxidant system enzymes as predictors of the development of metabolic disorders in primary obesity

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access


Aim. To assess the effectiveness of indicators of lipid peroxidation and the activity of antioxidant system enzymes in the early diagnosis of metabolic disorders.

Methods. The study included 269 women of fertile age with primary obesity. The control group consisted of 35 women. The clinical examination included identification of the type of obesity, whole-body fat percentage, the level of glycemia and the index of insulin resistance, biochemical markers of lipids, hormones (leptin and insulin), malondialdehyde and enzyme activity (peroxidase and catalase). The statistical significance of the differences was determined by using the inversion test. Spearman's rank correlation coefficient was used to assess the degree of relationship between quantitative characteristics, and scatter diagrams were used to compare two variables (Statistica software version 10.0).

Results. A statistically significant increase in basal and stimulated immunoreactive insulin was found in obese patients compared with the controls (p <0.01). Stimulated immunoreactive insulin levels, insulin resistance score (HOMA-IR) and the level of leptin in the group of patients with android obesity was higher than in the group with gynoid obesity (p <0.01). The relationship between the concentration of serum malondialdehyde and whole-body fat percentage was found to be more significant (r=0.412; p <0.001) than the relationship with the type of obesity (r=0.257; p <0.01). Positive correlations were found between serum malondialdehyde and insulin (r=0.35; p <0.001) and leptin (r=0.32; p <0.001) levels. The relationship between the concentration of serum malondialdehyde and the activity of enzyme systems was also noted. The activity of lipid peroxidation was higher in the group of patients with android obesity (malondialdehyde >3.3 μmol/L) compared with the group of patients with gynoid obesity. In the same group, a higher activity of enzyme systems was noted.

Conclusion. An increase in the concentration of serum malondialdehyde and the activity of enzyme systems should be considered as indicators of a high risk of developing metabolic syndrome.

Full Text

Restricted Access

About the authors

T V Nikishova

Kazan State Medical Academy — Branch of the Russian Medical Academy of Postgraduate Education

Author for correspondence.
ORCID iD: 0000-0002-0302-2251
SPIN-code: 4649-1596
Russian Federation, Kazan, Russia

I A Kurnikova

Peoples’ Friendship University of Russia

ORCID iD: 0000-0002-5712-9679
SPIN-code: 8579-9455
Russian Federation, Moscow, Russia


  1. World Health Organization. Obesity. (access date: 14.03.2021).
  2. Ametov A.S., Pashkova E.Yu., Ramazanova Z.D., Darsigova M.N. Obesity as a non-infectious epidemic of the XXI century. Modern ideas about the pathogenesis, risks and approaches to pharmacotherapy. Endokrinologiya: novosti, mneniya, obuchenie. 2019; 8 (2): 57–66. (In Russ.)
  3. Bray G.A., Heisel W.E., Afshin A., Jensen M.D., Dietz W.H., Long M., Kushner R.F., Daniels S.R., Wadden T.A., Tsai A.G., Hu F.B., Jakicic J.M., Ryan D.H., Wolfe B.M., Inge T.H. The science of obesity management: an Endocrine Society Scientific statement. Endocr. Rev. 2018; 39 (2): 79–132. doi: 10.1210/er.2017-00253.
  4. Kopp W. How western diet and lifestyle drive the pandemic of obesity and civilization diseases. Diabetes Metab. Syndr. Obes. 2019; 12: 2221–2236. doi: 10.2147/dmso.s216791.
  5. Vague J. Sexual differentiation; factor determining forms of obesity. Presse Med. 1947; 55 (30): 339.
  6. Shmeleva J.S., Zgurskaya A.S. Obesity and type 2 diabetes. Sinergia nauk. 2019; (36): 404–409. (In Russ.)
  7. Ostroumova O.D., Goloborodova I.V., Fomina V.M. Cardiovascular risk in type 2 diabetes patients. Kardiovaskularnaya terapia i profilaktika. 2018; 17 (4): 81–94. (In Russ.) doi: 10.15829/1728-8800-2018-4-81-94.
  8. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am. J. Clin. Nutr. 1956; 4 (1): 20–34. doi: 10.1093/ajcn/4.1.20.
  9. McCracken E., Monaghan M., Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin. Dermatol. 2018; 36 (1): 14–20. doi: 10.1016/j.clindermatol.2017.09.004.
  10. Matsuzawa Y., Funahashi T., Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J. Atheroscler. Thromb. 2011; 18 (8): 629–639. doi: 10.5551/jat.7922.
  11. Kramer C.K., Zinman B., Retnakaran R. Are meta­bolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann. Intern. Med. 2013; 159 (11): 758–769. doi: 10.7326/0003-4819-159-11-201312030-00008.
  12. Bell J.A., Kivimaki M., Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta‐analysis of prospective cohort studies. Obes. Rev. 2014; 15 (6): 504–515. doi: 10.1111/obr.12157.
  13. Seryogina D.S., Nikolayenkov I.P., Kuzminykh T.U. Obesity represents a strong pathogenetic link with the patho­logy of pregnancy and childbirth. Zhurnal akusherstva i zhenskikh bolezney. 2020; 69 (2): 73–82. (In Russ.) doi: 10.17816/JOWD69273-82.
  14. Pinkhasov B.B. Pathogenetic features of primary obesity and its types in women of reproductive age. Mezhdunarodnyy endokrinologicheskiy zhurnal. 2011; (8): 13–26. (In Russ.)
  15. Hill J.H., Solt C., Foster M.T. Obesity associated disease risk: the role of inherent differences and location of adipose depots. Horm. Mol. Biol. Clin. Investig. 2018; 33 (2): 7–9. doi: 10.1515/hmbci-2018-0012.
  16. Kuzmenko D.I., Udintsev S.N., Klimentyeva T.K., Serebrov V.Yu. Oxidative stress in adipose tissue as a primary link in pathogenesis of insulin resistance. Biomeditsinskaya khimiya. 2016; 62 (1): 14–21. (In Russ.) doi: 10.18097/pbmc20166201014.
  17. Gaschler M.M., Stockwell B.R. Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun. 2017; 482 (3): 419–425. doi: 10.1016/j.bbrc.2016.10.086.
  18. Gavrilov V.B., Gavrilova A.R., Khmara N.F. Changes in diene conjugates in plasma by ultraviolet absorption of heptane and isopropyl extracts. Laboratornoe delo. 1988; (2): 60–64. (In Russ.)
  19. Gavrilov V.B., Gavrilova A.R., Mazhul’ L.M. Methods of determining lipid peroxidation products in the serum using a thiobarbituric acid test. Voprosy medi­tsinskoy khimii 1987; 33 (1): 118–122. (In Russ.)
  20. Koro­lyuk M.A. Method for determination of catalase activity. Laboratornoe delo. 1988; (1): 16–19. (In Russ.)
  21. Popov T.A., Neykovskaya L.I. Method for determination of blood peroxidase activity. Gigiena i sanitariya. 1971; (10): 89–91. (In Russ.)
  22. Bulatova I.A., Shchekotova A.P., Karlysheva K.N. Features of oxidative stress in metabolic syndrome with fatty liver disease. Sovremennye. problemy nauki i obrazovaniya. 2014; (2): 307. (In Russ.)
  23. Povarova O.V., Gorodetskaya E.A., Kalenikova E.I., Medvedev O.S. Metabolic markers and oxidative stress in children’s obesity pathogenesis. Rossiyskiy vestnik perinatologii i pediatrii. 2020; 65 (1): 22–29. (In Russ.) doi: 10.21508/1027-4065-2020-65-1-22-29.
  24. Manna P., Jain S.K. Obesity, oxidative stress, adipose tissue dysfunction and the associated health risks: cau­ses and therapeutic strategies. Metab. Syndr. Relat. ­Disord. 2015; 10 (13): 423–444. doi: 10.1089/met.2015.0095.
  25. Taksali S.E., Caprio S., Dziura J., Dufour S., Calh A.M., Goodman T.R., Papademetris X., Burgert T.S., Pierpont B.M., Savoye M., Shaw M., Seyal A.A., Weiss R. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes. 2008; 57 (2): 367–371. doi: 10.2337/db07-0932.
  26. Vona R., Gambardella L., Cittadini C., Straface E., Pietraforte D. Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxid. Med. Cell. Longev. 2019; 2019: 8267234. doi: 10.1155/2019/8267234.

Supplementary files

Supplementary Files
1. Рис. 1. Корреляция показателя малонового диальдегида (МДА) и коэффициента «окружность талии/окружность бёдер» (ОТ/ОБ) (r=0,257) у пациенток с экзогенно-конституциональным ожирением

Download (23KB)
2. Рис. 2. Корреляция уровня малонового диальдегида (МДА) и инсулина (r=0,350) у пациенток с экзогенно-конституциональным ожирением

Download (31KB)

© 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies